Abstract
The conformation of the non-glycosylated recombinant form of the extracellar domain of rat MOG (rMOG(1-125)) dissolved in different solvent conditions was studied by CD spectroscopy. The results show that rMOG(1-125) exhibits a predominantly β sheet conformation in aqueous buffer solution at pH 7.5 and that this β-form is stabilized by zwitterionic phospholipids, DPC and LPCP. The a helical content of the protein can increase from 9% to up to 20% when TFE or anionic detergent LPAP and SDS are added.
Keywords: Myelin, Oligodendrocyte Glycoprotein (Mog), zwitterionic phospholipids, non-glycosylated
Protein & Peptide Letters
Title: Extracellular Domain Of Myelin Oligodendrocyte Glycoprotein (Mog) Exhibits Solvent-Dependent Conformational Transitions
Volume: 10 Issue: 5
Author(s): Maria Ngu-Schwemlein, Michele Corzett, Kevin H. Thornton, Rod Balhorn and Monique Cosman
Affiliation:
Keywords: Myelin, Oligodendrocyte Glycoprotein (Mog), zwitterionic phospholipids, non-glycosylated
Abstract: The conformation of the non-glycosylated recombinant form of the extracellar domain of rat MOG (rMOG(1-125)) dissolved in different solvent conditions was studied by CD spectroscopy. The results show that rMOG(1-125) exhibits a predominantly β sheet conformation in aqueous buffer solution at pH 7.5 and that this β-form is stabilized by zwitterionic phospholipids, DPC and LPCP. The a helical content of the protein can increase from 9% to up to 20% when TFE or anionic detergent LPAP and SDS are added.
Export Options
About this article
Cite this article as:
Ngu-Schwemlein Maria, Corzett Michele, Thornton H. Kevin, Balhorn Rod and Cosman Monique, Extracellular Domain Of Myelin Oligodendrocyte Glycoprotein (Mog) Exhibits Solvent-Dependent Conformational Transitions, Protein & Peptide Letters 2003; 10 (5) . https://dx.doi.org/10.2174/0929866033478672
DOI https://dx.doi.org/10.2174/0929866033478672 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage
Current Neuropharmacology Merging Transport Data for Choroid Plexus with Blood-Brain Barrier to Model CNS Homeostasis and Disease More Effectively
CNS & Neurological Disorders - Drug Targets Angiopoietin-1 and C16 Peptide Attenuate Vascular and Inflammatory Responses in Experimental Allergic Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Therapeutic Strategies To Prevent Neurodegeneration And Promote Regeneration In Multiple Sclerosis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Mechanisms of Mononuclear Phagocyte Recruitment in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets The Role of Adenosine in Rheumatoid Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Synthesis of Drugs and Biorelevant N-heterocycles Employing Recent Advances in C-N Bond Formation
Current Organic Chemistry Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology
Current Neuropharmacology Commentary: Intravenous Immunoglobulin (IVIG) Therapy for Patients with Langerhans Cell Histiocytosis (LCH)-Related Neurodegenerative Diseases of the CNS
CNS & Neurological Disorders - Drug Targets The Heme Oxygenase System and Type-1 Diabetes
Current Pharmaceutical Design APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator
Endocrine, Metabolic & Immune Disorders - Drug Targets Tryptophan Catabolism in IDO+ Plasmacytoid Dendritic Cells
Current Drug Metabolism Nanostructures for Drug Delivery to the Brain
Current Medicinal Chemistry Gene Expression Studies in Multiple Sclerosis
Current Genomics Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions
Current Medicinal Chemistry The Role of Stem Cells in Muscular Dystrophies
Current Gene Therapy The Potential Role of the Endocannabinoid System in the Control of Multiple Scleorsis
Current Medicinal Chemistry - Central Nervous System Agents Thymosin β4 Protein Therapy for Cardiac Repair
Current Pharmaceutical Design